Applied StemCell Raises $19M

The round was headed by HerMed Capital Other investors included Ping An Ventures, Vi-Ventures and BioSciKin. The company intends to use the proceeds to accelerate the development of its pipeline, expand its gene editing platform technology and continue to strengthen its leading portfolio of intellectual property.

‘ASC is pleased to welcome this group of health investors to our existing union. We feel that this funding reflects the strong support for our business model and position us to move our company and strategy forward quickly,” said Ruhong Jiang, Ph.D. D. D. , ASC Co-founder and Chief Executive Officer ‘Our mission is to leverage our extensive expertise in stem cell biology and genome editing to develop cutting-edge technologies that enable scientific discovery and advancement of human medicine. ”

Jerry Xiao, Ph.D. D. D. The Managing Director of HerMed Capital said, “We are excited to include Applied StemCell as the newest member of our portfolio. By combining the strong technical foundation of Applied StemCell with the expertise and infrastructure of HerMed, we believe that we can help accelerate the translation of ASC’s scientific advances into transformative therapy. ”

Ping An Ventures Managing Director Jiang Zhang said, “We were immediately struck by the vision and strategy of Applied StemCell and are confident that the company has the leadership and expertise to deliver innovative therapeutics using its gene editing technology. ”

Strategy and Pipeline of the ASC

ASC’s strategy is to use its core strengths to expand its IP portfolio and develop a strong therapeutic pipeline based on its patented gene editing technology. The company’s expertise in the use of genome editing for both animal and cell model generation, as well as its portfolio of improved genome editing technologies, make it uniquely positioned to develop transformative solutions to pressing medical challenges.

Applied StemCell’s therapeutic pipeline will focus heavily on monogenic blood disorders that are characterized by high genetic penetration. Such diseases are a strong point for a company specializing in the genetic engineering of stem cell lineages.

About StemCell Applied

StemCell Applied, Inc. The leading stem cell and gene-editing company focuses on the development of products and therapeutics that are enabled by its proprietary TARGATT and CRISPR/Cas9 gene-editing platform technologies. Please visit www for more information. Applied Temcell Come on,

About HerMed Capital City

HerMed Capital Fund is a private equity fund committed to promoting innovation in the healthcare sector. The Fund is a partnership between Fosun Pharmaceutical Group-a leading Chinese healthcare conglomerate with a total market capitalization of US$7. 32B-and SK Group-a leading conglomerate and economic pillar in Korea, accounting for 11% of the country’s GDP and 11% of exports. The partnership combines unmatched expertise in the biopharmaceutical sector with a wide network of healthcare and distribution channels.

About the Ping and Ventures

Ping An Ventures is a professional VC firm run by Ping An Insurance (Group) Company of China, with a focus on financing emerging innovations. The firm is committed to helping its portfolio companies grow and succeed by providing not only funding, but also management advice, introductions to key opinion leaders and partners, and other resources needed. Fortune 100 Global Company, Chairman & CEO of Ping An, was named to Fortune’s 25 Top Business Leaders in 2015.

On BioSciKin

BSK Venture is a life science fund that focuses on driving innovation in the biomedical community through the development of an integrated life science campus. The objective of the Fund is to create a network of portfolio companies that create an internal eco-system to enable technological advances. Investments are strategically targeted and focus on global regions and start-ups with the greatest potential to generate transformative technologies.

Around VI Ventures

VI Ventures is a boutique firm providing seed, venture and growth financing to ambitious and innovative companies in the fields of TMT and MedTech. In addition, the company works as a partner with its portfolio companies, contributing expertise in essential services, including branding, marketing, channel development, overseas expansion, human resources and finance. The firm invests in early-stage, cross-border technology companies and helps to enter the massive and fast-growing markets of China and Asia.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Applied%20StemCell/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co